Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results

NEXT STORY
Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares
PREV STORY
Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

author_avatar
NASDAQ Market News

MolecularMD Launches Validated Tumor Mutation Burden Assay for Immuno-Oncology Clinical Trial Services

PORTLAND, Ore., Aug. 22, 2018 (GLOBE NEWSWIRE) -- MolecularMD today announces it has validated ...

author_avatar
NASDAQ Market News

Annual results for the year ended 31 March 2020

author_avatar
NASDAQ Market News